CN117157092A - 控制免疫细胞活性的方法 - Google Patents

控制免疫细胞活性的方法 Download PDF

Info

Publication number
CN117157092A
CN117157092A CN202280026923.7A CN202280026923A CN117157092A CN 117157092 A CN117157092 A CN 117157092A CN 202280026923 A CN202280026923 A CN 202280026923A CN 117157092 A CN117157092 A CN 117157092A
Authority
CN
China
Prior art keywords
immunotherapeutic agent
binding
molecule
cellular immunotherapeutic
target antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280026923.7A
Other languages
English (en)
Chinese (zh)
Inventor
P·施莱格尔
J·A·巴登
李子多
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosceptre (Aust) Pty Ltd
Original Assignee
Biosceptre (Aust) Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021901030A external-priority patent/AU2021901030A0/en
Application filed by Biosceptre (Aust) Pty Ltd filed Critical Biosceptre (Aust) Pty Ltd
Publication of CN117157092A publication Critical patent/CN117157092A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202280026923.7A 2021-04-08 2022-04-08 控制免疫细胞活性的方法 Pending CN117157092A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021901030A AU2021901030A0 (en) 2021-04-08 Methods for controlling immune cell activity
AU2021901030 2021-04-08
PCT/AU2022/050311 WO2022213154A1 (en) 2021-04-08 2022-04-08 Methods for controlling immune cell activity

Publications (1)

Publication Number Publication Date
CN117157092A true CN117157092A (zh) 2023-12-01

Family

ID=83544929

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280026923.7A Pending CN117157092A (zh) 2021-04-08 2022-04-08 控制免疫细胞活性的方法

Country Status (9)

Country Link
US (1) US20250282844A1 (cg-RX-API-DMAC7.html)
EP (1) EP4319793A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024513485A (cg-RX-API-DMAC7.html)
CN (1) CN117157092A (cg-RX-API-DMAC7.html)
AU (1) AU2022253547A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023020659A2 (cg-RX-API-DMAC7.html)
CA (1) CA3213042A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023011807A (cg-RX-API-DMAC7.html)
WO (1) WO2022213154A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026507807A (ja) * 2023-03-08 2026-03-06 バイオセプター (オースト) プロプライエタリー・リミテッド 機能不全p2x7受容体に結合するためのキメラ抗原受容体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101555283B (zh) * 2001-01-17 2012-03-21 生物权威国际有限公司 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途
WO2003020762A1 (en) * 2001-09-03 2003-03-13 Intreat Pty Limited Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions
AU2009266430B2 (en) * 2008-07-04 2014-08-14 Biosceptre International Limited Anti- P2X7 peptides and epitopes
ES2699753T3 (es) * 2014-01-29 2019-02-12 Biontech Ag Mimótopos peptídicos de claudina 18.2 y sus usos
EP3484455A2 (en) * 2016-07-15 2019-05-22 Novartis AG Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
US10986601B2 (en) * 2017-07-26 2021-04-20 Panoramic Power Ltd. System and method for timing synchronization of a self-powered power sensor
CA3211323A1 (en) * 2021-03-11 2022-09-15 Patrick Schlegel Novel cell therapy system

Also Published As

Publication number Publication date
WO2022213154A1 (en) 2022-10-13
US20250282844A1 (en) 2025-09-11
EP4319793A4 (en) 2025-03-19
MX2023011807A (es) 2024-01-05
AU2022253547A1 (en) 2023-10-05
BR112023020659A2 (pt) 2023-12-05
JP2024513485A (ja) 2024-03-25
CA3213042A1 (en) 2022-10-13
EP4319793A1 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
CN108884164B (zh) 用于免疫疗法的经修饰细胞
TWI879715B (zh) 調節細胞表達的生物活性之結合分子
JP2022109915A (ja) Cd80バリアント免疫調節タンパク質およびその使用
KR102758545B1 (ko) Ctla-4 변이체 면역조절 단백질 및 이의 용도
RS64870B1 (sr) Imunomodulatorni proteini varijante pd-l1 i njihove upotrebe
US20240368282A1 (en) Methods and compositions for stimulating immune activity
WO2020244526A1 (zh) 一种抗ceacam5的单克隆抗体及其制备方法和用途
TW201920275A (zh) 藉由細胞表現之調控生物活性的抗體
CN110088127A (zh) Cd155变体免疫调节蛋白及其用途
TW201920264A (zh) 藉由細胞表現之調控生物活性的結合分子
KR20170057298A (ko) Cd19에 특이적인 항체 및 키메라 항원 수용체
CN111727057A (zh) 与lag3和pd1结合的治疗分子
CN114302733B (zh) 抗纽约食管鳞状细胞癌1(ny-eso-1)抗原结合蛋白及其使用方法
CN119143873A (zh) 激动性ltbr抗体以及包含它们的双特异性抗体
WO2022247795A1 (zh) 靶向Claudin18.2的纳米抗体及其用途
CN116033919A (zh) 用于免疫细胞中衔接子的诱导型表达的系统
US20250282844A1 (en) Methods for controlling immune cell activity
US20260061051A1 (en) Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
KR20230146032A (ko) Tgf-b 신호전달을 조절하기 위한 세포 치료 조성물 및 방법
HK40128378A (en) Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
HK40114235A (en) Agonistic ltbr antibodies and bispecific antibodies comprising them
HK40114510A (en) Agonistic ltbr antibodies and bispecific antibodies comprising them
TW202602909A (zh) 新穎介白素-7免疫結合物
CN119768434A (zh) 一种双特异性抗体及其应用
CN118434768A (zh) 激动性ltbr抗体以及包含它们的双特异性抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination